Publications

Header Image
  • Barnes GD, Kaatz S, Golgotiu V, Gu X, Leidal A, Kobeissy A, Haymart B, Kline-Rogers E, Kozlowski J, Almany S, Leyden T, Froehlich JB.Use of warfarin for venous thromboembolism prophylaxis following knee and hip arthroplasty: results of the Michigan Anticoagulation Quality Improvement Initiative (MAQI(2)).J Throm Thrombolysis 2012;Jul 14
  • Geoffrey D. Barnes, Scott Kaatz , Julia Winfield , Xiaokui Gu, Brian Haymart, Eva Kline-Rogers, Jay Kozlowski, Dennis Beasley, Steve Almany, Tom Leyden, James B. Froehlich.Warfarin use in atrial fibrillation patients at low risk for stroke: analysis of the Michigan Anticoagulation Quality Improvement Initiative (MAQI2). J Thromb Thrombolysis. 2013 May 8.
  • Geoffrey D. Barnes, Xiaokui Gu, Brian Haymart, Eva Kline-Rogers, Steve Almany, Jay Kozlowski, Dennis Besley, Gregory D. Krol, James B. Froehlich, Scott Kaatz. The Predictive Ability of the CHADS2 and CHA2DS2-VASc Scores for Bleeding Risk in Atrial Fibrillation: The MAQI2 Experience. Thrombosis Research 134 (2014) 294–299
  • Eric Puroll, Steven T. Heidt, Brian Haymart, James B. Froehlich, and Eva Kline-Rogers. AREDS Formula, Warfarin, and Bleeding: A Case Report from the Michigan Anticoagulation Quality Improvement Initiative. Case Reports in Medicine Volume 2014 (2014). doi.org/10.1155/2014/754147
  • Geoffrey D. Barnes, Eva Kline-Rogers. Engaging with quality improvement in anticoagulation management. J Thromb Thrombolysis (2015) 39:403–409
  • Putnam A, Gu X, Haymart B, Kline-Rogers E, Almany S, Kozlowski J, Krol GD, Kaatz S, Froehlich JB, Barnes GD. The changing characteristics of atrial fibrillation patients treated with warfarin. J Thromb Thrombolysis. 2015 Jul 1.
  • Minhas A.S., Jiang Q., Gu X., Haymart B., Kline-Rogers E., Almany S., Kozlowski J., Krol G.D., Kaatz S., Froehlich J.B., Barnes G.D. Renal function in atrial fibrillation patients switched from warfarin to a direct oral anticoagulant. J Thromb Thrombolysis (2016) 42:566–572
  • Hale Z.D., Kong X., Haymart B., Gu X., Kline-Rogers E., Almany S., Kozlowski J., Krol G.D., Kaatz S., Froehlich J.B., Barnes G.D.Prescribing trends of atrial fibrillation patients who switched from warfarin to a direct oral anticoagulant. Journal of Thrombosis and Thrombolysis.Nov. 2016.
  • Jordan K. Schaefer, Suman L. Sood, Brian Haymart, Xiaokui Gu, Eva Kline-Rogers, Steven L. Almany, Jay H. Kozlowski, Gregory D. Krol, Scott Kaatz, James B. Froehlich and Geoffrey D. Barnes. Sociodemographic factors in patients continuing warfarin vs those transitioning to direct oral anticoagulants. Blood Advances. December 2017. Volume 1, Number 26.
  • Barnes G.D., Kaatz S., Lopez A., Gu X., Kozlowski J., Krol G.D., Froehlich J.B. Discontinuation of Warfarin Therapy for Patients With Atrial Fibrillation: The Michigan Anticoagulation Quality Improvement Initiative Experience. JAMA Cardiology Published online January 4, 2017
  • Christopher M. Graves, BA; Brian Haymart, RN, MS; Eva Kline-Rogers, MS, NP; Geoffrey D. Barnes, MD, MSc; Linda K. Perry, RN, BSN; Denise Pluhatsch, RN, BSN; Nannette Gearhart, RN, MSN; Helen Gikas, RN; Noelle Ryan, PharmD; Brian Kurtz, PharmD. Root Cause Analysis of Adverse Events in an Outpatient Anticoagulation Management Consortium. The Joint Commission Journal on Quality and Patient Safety 2017; 43:299–307
  • Geoffrey D. Barnes, Sevan Misirliyan, Scott Kaatz, Elizabeth A. Jackson, Brian Haymart, Eva Kline-Rogers, Jay Kozlowski, Gregory Krol, James B. Froehlich and Anne Sales. Barriers and facilitators to reducing frequent laboratory testing for patients who are stable on warfarin: a mixed methods study of de-implementation in five anticoagulation clinics. Implementation Science 2017 12:87. DOI: 10.1186/s13012-017-0620-x
  • Deborah DeCamillo, RN, BSN; Elizabeth Renner, PharmD. ICHECK’D: Mnemonic approach assists in caring for patients receiving direct oral anticoagulant. Cardiology Today, January 2018. https://goo.gl/Hpmjcr
  • Jacob E Kurlander, MD, MS , Geoffrey D Barnes, MD, MS, Michelle A. Anderson, MD, MSc, Brian Haymart, RN, MSc, Eva Kline-Rogers, NP, Scott Kaatz, DO, MSc, Sameer D Saini, MD, MS, Sarah L. Krein, PhD, RN, Caroline R. Richardson,MD, James B Froehlich, MD, MPH. Mind the gap: Results of a multispecialty survey on coordination of care for peri-procedural anticoagulation. J Thromb Thrombolysis. 2018 Apr;45(3):403-409. doi: 10.1007/s11239-018-1625-2.
  • G. D. BarnesX. KongD. ColeB. HaymartE. Kline‐RogersS. AlmanyM. DahuM. EkolaS. Kaatz J. KozlowskiJ. B. Froehlich Extended International Normalized Ratio Testing Intervals for Warfarin-treated Patients. Journal of Thrombosis and Haemostasis. 16: 1307–1312 DOI: 10.1111/jth.14150
  • Hughey AB, Gu X, Haymart B, Kline-Rogers E, Almany S, Kozlowski J, Besley D, Krol GD, Ahsan S, Kaatz S, Froehlich JB, Barnes GD. Warfarin for Prevention of Thromboembolism in Atrial Fibrillation: Comparison of Patient Characteristics and Outcomes of the "Real-World" Michigan Anticoagulation Quality Improvement Initiative (MAQI2) Registry to the RE-LY, ROCKET-AF, and ARISTOTLE Trials. J Thromb Thrombolysis. 2018 Oct;46(3):316-324. doi: 10.1007/s11239-018-1698-y.
  • Kurlander JE, Gu X, Scheiman JM, et al. Missed Opportunities to Prevent Upper GI Hemorrhage: The Experience of the Michigan Anticoagulation Quality Improvement Initiative. Vasc Med. 2019 Feb 27:1358863X18815971. doi: 10.1177/1358863X18815971
  • Schaefer J.K., Li Y., Gu X., Souphis N.M., Haymart B., Kline-Rogers E., Almany S.L., Kaatz S., Kozlowski J.H., Krol G.D., Sood S.L., Froehlich J.B., Barnes G.D.. Association of Adding Aspirin to Warfarin Therapy Without an Apparent Indication With Bleeding and Other Adverse Events. JAMA Intern Med. doi:10.1001/jamainternmed.2018.7816
  • Gruca, M.M., Li, Y., Kong, X. et al. J Thromb Thrombolysis. Creatinine monitoring patterns in the setting of direct oral anticoagulant therapy for non-valvular atrial fibrillation. October 2019, Volume 48, Issue 3, pp 500–505. https://doi.org/10.1007/s11239-019-01883-0
  • DeCamillo D, Ellsworth S, Kaatz S, Barnes GD. Use of apixaban and rivaroxaban in young adults with acute venous thromboembolism: a multi-center retrospective case series. J Thromb Thrombolysis. 2020 Nov;50(4):844-848. doi: 10.1007/s11239-020-02095-7. PMID: 32219722.
  • Geoffrey D. Barnes, Yun Li, Xiaokui Gu, Brian Haymart, Eva Kline-Rogers, Mona Ali, Jay Kozlowski, Gregory Krol, James B. Froehlich, Scott Kaatz. Periprocedural bridging anticoagulation in patients with venous thromboembolism: A registry‐based cohort study. J Thromb Haemost. 2020;18:2025–2030. 
  • Dawson T, DeCamillo D, Kong X, Shensky B, Kaatz S, Krol GD, Ali M, Haymart B, Froehlich JB, Barnes GD. Correcting Inappropriate Prescribing of Direct Oral Anticoagulants: A Population Health Approach. J Am Heart Assoc. 2020 Nov 17;9(22):e016949. doi: 10.1161/JAHA.120.016949. Epub 2020 Nov 5. PMID: 33150804.
  • Julian Neshewat, Amanda Wasserman, Constantina Alexandris-Souphis, Brian Haymart, Delaney Feldeisen, Xiaowen Kong, Rebecca S. Harvey, Melissa Pynnonen, James B. Froehlich, Eva Kline-Rogers, Geoffrey D. Barnes. Reduction in epistaxis and emergency department visits in patients taking warfarin after implementation of an education program. Thrombosis Research. Volume 199. 2021. Pages 119-122. https://doi.org/10.1016/j.thromres.2021.01.007
  • Schaefer J.K., Errickson J., Li Y., Kong X., Alexandris-Souphis T., Ali M.A., Decamillo D., Haymart B., Kaatz S., Kline-Rogers E., Kozlowski J.H., Krol G.D., Shankar S.R., Sood S.L., Froehlich J.B., Barnes G.D. Adverse Events Associated With the Addition of Aspirin to Direct Oral Anticoagulant Therapy Without a Clear Indication. JAMA Intern Med. Published online April 19, 2021. doi:10.1001/jamainternmed.2021.1197
  • Hanigan S, Kong X, Haymart B, et al. Standard Versus Higher Intensity Anticoagulation for Patients With Mechanical Aortic Valve Replacement and Additional Risk Factors for Thromboembolism. Am J Cardiol 2021;159:100−106. doi:10.1001/jamainternmed.2021.1197. doi.org/10.1016/j.amjcard.2021.08.023
  • Sheikh MA, Kong X, Haymart B, et al. Comparison of temporary interruption with continuation of direct oral anticoagulants for low bleeding risk procedures. Thromb Res. 2021;203:27-32. doi:10.1016/j.thromres.2021.04.006
  • Feldeisen T, Alexandris-Souphis C, Haymart B, et al. Anticoagulation Changes Following Major and Clinically Relevant Nonmajor Bleeding Events in Non-valvular Atrial Fibrillation Patients [published online ahead of print, 2021 Dec 28]. J Pharm Pract. 2021;8971900211064189. doi:10.1177/08971900211064189
  • Hallie B Remer, Xiaokui Gu, Brian Haymart, Geoffrey D Barnes, Mona A Ali, Eva Kline-Rogers, Tina Alexandris-Souphis, Jay Kozlowski, James Froehlich, Vinay Shah, Gregory D Krol, Scott Kaatz; Management Strategies Following Slightly Out of Range INRs: Watchful Waiting vs. Dose Changes. Blood Adv 2022; bloodadvances.2021006454. doi: https://doi.org/10.1182/bloodadvances.2021006454
  • Melinda Song, Brian Haymart, Xiaowen Kong, Mona Ali, Scott Kaatz, Jay Kozlowski, Gregory Krol, Jordan Schaefer, James B Froehlich, and Geoffrey D Barnes. Association of adding antiplatelet therapy to warfarin for management of venous thromboembolism with bleeding and other adverse events. Vasc Med. 2022;27(4):382-384. doi:10.1177/1358863X221089333
  • DeCamillo D, Haymart B, Barnes GD. Adverse events in patients taking apixaban or rivaroxaban who have undergone bariatric surgery: a retrospective case series. Journal of Thrombosis and Thrombolysis. 2022 Apr;53(3):601-606. DOI: 10.1007/s11239-021-02573-6. PMID: 34559367.
  • Haymart B, Barnes GD, Kong X, Ali M, Kline-Rogers E, DeCamillo D, Kaatz S. Comparison of Patient Outcomes Before and After Switching From Warfarin to a Direct Oral Anticoagulant Based on Time in Therapeutic Range Guideline Recommendations. JAMA Netw Open. 2022 Jul 1;5(7):e2222089. doi: 10.1001/jamanetworkopen.2022.22089. PMID: 35834255; PMCID: PMC9284330.
  • Schaefer J.K., Errickson J., Gu X., Alexandris-Souphis T., Ali M.A., Haymart B., Kaatz S., Kline-Rogers E., Kozlowski J.H., Krol G.D., Shah V., Sood S.L., Froehlich J.B., Barnes G.D. Assessment of an Intervention to Reduce Aspirin Prescribing for Patients Receiving Warfarin for Anticoagulation. JAMA Netw Open. 2022;5(9):e2231973. doi:10.1001/jamanetworkopen.2022.31973
  • Elizabeth Joyce, Brian Haymart, Xiaowen Kong, Mona A. Ali, Mara Carrigan, Scott Kaatz, Vinay Shah, Eva Kline‐Rogers, Jay Kozlowski, James B. Froehlich and Geoffrey D. Barnes. Length of Anticoagulation in Provoked Venous Thromboembolism: A Multicenter Study of How Real-World Practice Mirrors Guideline Recommendations [published online ahead of print, 2022 Oct 26]. J Am Heart Assoc. 2022;e025471. doi:10.1161/JAHA.122.025471
  • Jeffrey Lee, Xiaowen Kong, Brian Haymart, Eva Kline‐Rogers, Scott Kaatz, Vinay Shah, Mona A. Ali, Jay Kozlowski, James Froehlich, Geoffrey D. Barnes. Outcomes in patients undergoing periprocedural interruption of warfarin or direct oral anticoagulants. J Thromb Haemost. 2022; 20: 2571- 2578. doi: 10.1111/jth.15850
  • Delaney Feldeisen, Constantina Alexandris-Souphis, Brian Haymart, Xiaokui Gu, Linda Perry, Stephanie Watts, Renee Kozlowski, Jay Kozlowski, James B. Froehlich, Geoffrey D. Barnes & Eva Kline-Rogers. Higher OAK (Oral Anticoagulation Knowledge) score at baseline associated with better TTR (Time in Therapeutic Range) in patients taking warfarin. Journal of Thrombosis and Thrombolysis volume 55, pages141–148 (2023)
  • Deborah DeCamillo, Brian Haymart, Xiaowen Kong, Scott Kaatz, Mona A Ali, Geoffrey D Barnes. Adverse events in low versus normal body weight patients prescribed apixaban for atrial fibrillation. Journal of Thrombosis and Thrombolysis volume 55, pages 680–684 (2023)
  • Feldeisen T, Alexandris-Souphis C, Haymart B, et al. Anticoagulation Changes Following Major and Clinically Relevant Nonmajor Bleeding Events in Non-valvular Atrial Fibrillation Patients. J Pharm Pract. 2023 Jun;36(3):542-547. doi: 10.1177/08971900211064189. Epub 2021 Dec 28. PMID: 34962835.
  • Brian Haymart, Xiaowen Kong, Mona Ali, Jordan K. Schaefer, James B. Froehlich, Noelle Ryan, Beverly Stallings, Geoffrey D. Barnes, Scott Kaatz. Prevalence of Guideline-Discordant Aspirin Use and Associated Adverse Events in Patients on Warfarin for Mechanical Valve Replacement. The American Journal of Medicine, 2024, ISSN 0002-9343, https://doi.org/10.1016/j.amjmed.2024.01.015.
  • Deborah DeCamillo, Lindsey A. Herrel, Brian Haymart, Ahmaad Latfolla, Geoffrey D. Barnes, Unexplained Hematuria in Direct Oral Anticoagulant Use: A Single-Center Retrospective Case Series. Research and Practice in Thrombosis and Haemostasis. 2024,102404, ISSN 2475-0379,https://doi.org/10.1016/j.rpth.2024.102404
  • Dobry P, Edwin SB, Haymart B, et al. Treatment of Atrial Fibrillation and Venous Thromboembolism with Factor Xa Inhibitors in Severely Obese Patients. J Thromb Haemost. Published online September 5, 2024. doi:10.1016/j.jtha.2024.08.009
  • Jordan K. Schaefer, Josh Errickson, Xiaowen Kong, Mona A. Ali, Deborah DeCamillo, Subhash Edupuganti, Brian Haymart, Scott Kaatz, Eva Kline-Rogers, Jay H. Kozlowski, Gregory D. Krol, Suman L. Sood, James B. Froehlich, Geoffrey D. Barnes. Outcomes of direct oral anticoagulants with aspirin vs warfarin with aspirin: a registry-based cohort study, Research and Practice in Thrombosis and Haemostasis, Volume 8, Issue 4, 2024,102449,ISSN 2475-0379, https://doi.org/10.1016/j.rpth.2024.102449.
  • Herron GC, DeCamillo D, Kong X, et al. Timing of Off-Label Dosing of Direct Oral Anticoagulants in Three Large Health Systems. Thromb Haemost. Published online July 30, 2024. doi:10.1055/a-2365-8681
  • Ardeshna N, Feldeisen T, Kong X, et al. Comparing DOAC and warfarin outcomes in an obese population using the ‘real-world’ Michigan Anticoagulation Quality Improvement Initiative (MAQI2) registry. Vascular Medicine. 2024;0(0). doi:10.1177/1358863X241264478
  • Co A, Kazaglis C, DeCamillo D, Haymart B, Rajakumar B, Barnes GD. Prevalence of discussions around left atrial appendage occlusion as a treatment option in patients on oral anticoagulation experiencing a major bleeding event. Thromb Res. 2025 Jan;245:109239. doi: 10.1016/j.thromres.2024.109239. Epub 2024 Dec 4. PMID: 39644619.
  • Burke KS, Kong X, Haymart B, DeCamillo D, Ali M, Barnes G, Kaatz S. Comparing rates of clinically relevant epistaxis in patients taking warfarin versus direct oral anticoagulants. Res Pract Thromb Haemost. 2024 Nov 20;8(8):102630. doi: 10.1016/j.rpth.2024.102630. PMID: 39758287; PMCID: PMC11699722.
  • Suzanne Irani, Xiaokui Gu, Brian Haymart, Constantina Alexandris-Souphis, Helen Gikas, Mona Ali, Scott Kaatz, Joey Maniaci, Linda Perry, Mary Jo Deyoung, Stacy Ellsworth, James Froehlich, Eva Kline Rogers, Noelle Ryan, Geoffrey Barnes, Analysis of quality measures before and after switching care models in MAQI2 anticoagulation clinics, Thrombosis Research, Volume 247, 2025, 109278, ISSN 0049-3848, https://doi.org/10.1016/j.thromres.2025.109278.
  • Schaefer JK, Errickson J, Kong X, Ali MA, Chipalkatti N, Haymart B, Kaatz S, Krol GD, Sood SL, Froehlich JB, Barnes GD. A Comparison of Outcomes With Apixaban, Rivaroxaban, and Warfarin for Atrial Fibrillation and/or Venous Thromboembolism. JACC Adv. 2025 May;4(5):101714. doi: 10.1016/j.jacadv.2025.101714. Epub 2025 Apr 25. PMID: 40286370; PMCID: PMC12235406.
  • Kurlander JE, Helminski D, Tao X, Saini SD, Krein SL, Richardson CR, Kidwell KM, Lanham MSM, Henstock JL, Resnick J, Song M, Vries R, Resnicow K, Ha N, Haymart B, Alexandris-Souphis C, Froehlich JB, Barnes GD. An Intervention to Reduce Antiplatelet Use without Gastroprotection in Patients Using Warfarin: The AEGIS Cluster Randomized Trial. Thromb Haemost. 2025 May 2. doi: 10.1055/a-2544-6104. Epub ahead of print. PMID: 40315868.